Confronted with value uncertainty and high patient demand, payers are considering managed access approaches that re-evaluate adopted technologies or that manage the risk of early patient access through risk-sharing arrangements between developers and healthcare systems. Regulators, payers, pharmaceutical companies and HTA organizations are calling for case studies in which to test methods adapted to LC-HTA.
In the context of our precision oncology case studies, this research activity aims to:
- Develop and apply LC-HTA methods for reimbursed technologies (i.e., OncoPanel and Myeloid Panel)
- Characterize the economic impacts of pilot precision oncology programs (i.e., Personalized Onco-genomics [POG – NCT02155621] and the Ontario-wide Cancer Targeted Nucleic Acid Evaluation [OCTANE – NCT02906943] programs)
- Compare managed access and risk sharing strategies (i.e., leasing reimbursement, access with evidence development, and rebate reimbursement) in the presence of evidentiary uncertainty